Olgu Sunumu

Two cases of dermatomyositis with anti-cN1A antibody positivity

Cilt: 47 Sayı: 1 29 Mart 2025
PDF İndir
TR EN

Two cases of dermatomyositis with anti-cN1A antibody positivity

Abstract

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune-mediated disorders. One of the most important developments in recent years regarding IIMs is the clinical use of myositis-specific antibodies and myositis-associated antibodies. The identification of anti-cytosolic 5’-nucleotidase 1A (anti-cN1A), one of the myositis-associated antibodies, represents significant progress in understanding inclusion body myositis (IBM), with research focusing on its role in predicting survival, diagnostic potential, clinical phenotype, and histopathological correlations. With the increasing use of autoantibodies in recent years, it is essential to understand their specificity and sensitivity properties. We presented two cases of dermatomyositis with positive anti-cN1A antibodies, which are known to have high specificity in IBM. One of the cases is a male patient, and IBM was included in the differential diagnosis because of anti-cN1A antibody positivity and resistance to first-line immunosuppressive therapy. The other case is a female patient diagnosed with dermatomyositis twelve years ago, with a myositis antibodies panel performed during a disease flare revealing anti-cN1A antibody positivity.

Keywords

Kaynakça

  1. 1- Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. Published 2021 Dec 2. doi:10.1038/s41572-021-00321-x
  2. 2- Allameen NA, Salam S, Reddy V, Machado PM. Inclusion body myositis and immunosenescence: current evidence and future perspectives. Rheumatology (Oxford). Published online November 6, 2024. doi:10.1093/rheumatology /keae614
  3. 3- Allameen NA, Ramos-Lisbona AI, Wedderburn LR, Lundberg IE, Isenberg DA. An update on autoantibodies in the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2025;21 (1):46-62. doi:10.1038/s41584-024-01188-4
  4. 4- Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408-418. doi:10.1002/ana. 23840
  5. 5- Salam S, Dimachkie MM, Hanna MG, Machado PM. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clin Exp Rheumatol. 2022;40(2):384-393. doi:10.55563/clinexprheumatol/r625rm
  6. 6- Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):87. Published 2021 Dec 2. doi:10.1038/s41572-021-00325-7
  7. 7- Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397-407. doi:10.1002/ana.23822
  8. 8- Mavroudis I, Knights M, Petridis F, Chatzikonstantinou S, Karantali E, Kazis D. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis. J Clin Neuromuscul Dis. 2021;23(1):31-38. doi:10.1097/CND.0000000000000353

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Hizmetleri ve Sistemleri (Diğer)

Bölüm

Olgu Sunumu

Erken Görünüm Tarihi

29 Mart 2025

Yayımlanma Tarihi

29 Mart 2025

Gönderilme Tarihi

26 Ekim 2024

Kabul Tarihi

8 Mart 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 47 Sayı: 1

Kaynak Göster

AMA
1.Tay K, Toker Dinçer Z, Parlar K, Ünverengil G, Uğurlu S. Two cases of dermatomyositis with anti-cN1A antibody positivity. CMJ. 2025;47(1):55-58. doi:10.7197/cmj.1552096